Short supply of Provenge constrains Dendreon's sales; Sanofi advances dengue vaccine;

 @FierceBiotech: Biogen restructuring claims 650 jobs. Article | Follow @FierceBiotech

> Dendreon announced $79.3 million in losses for the third quarter, despite its prostate cancer drug Provenge's growing sales. The company expects revenue to pick up in 2011, with half of its forecasted $350 to $400 million coming in the fourth quarter of that year. Article

> Sanofi Pasteur's dengue vaccine has entered its first Phase III clinical study in Australia. The study is part of a global Phase III clinical study program aimed at advancing the development of a novel vaccine for the prevention of dengue disease in children and adults. Report

> A study published in the New England Journal of Medicine showed that Novartis' drug Afintor reduced the size of subependymal giant cell astrocytomas, which are brain tumors associated with 20 percent of tuberous sclerosis patients. Novartis release

> German drug company 4SC AG announced positive preliminary Phase IIa results for its interleukin-17 inhibitor vidofludimus as an inflammatory bowel disease treatment. The drug enhanced patients' response rates to 88.5 percent, compared to the placebo's 20 percent over a 12 week treatment window. 4SC release

> Derek Lowe of In The Pipeline looks at pharmas, biotechs and universities and breaks down the numbers on where drugs come from. Post

 And Finally... Higher income parents are increasingly forgoing kids' vaccinations. Article

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.